<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; concerns</title>
	<atom:link href="http://www.tapanray.in/tag/concerns/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Scandalizing Biosimilar Drugs With Safety Concerns</title>
		<link>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=scandalizing-biosimilar-drugs-with-safety-concerns</link>
		<comments>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/#comments</comments>
		<pubDate>Mon, 25 Aug 2014 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12]]></category>
		<category><![CDATA[badmouthing]]></category>
		<category><![CDATA[Bio]]></category>
		<category><![CDATA[Biologic]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GPhA]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[INN]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[proposal]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[scandalizing]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[Year]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5772</guid>
		<description><![CDATA[With the patent expiry of exorbitantly priced biologic medicines, introduction of biosimilar drugs are expected to improve their access to millions of patients across the world, saving billions of dollars in healthcare costs in the subsequent years. According to an &#8230; <a href="http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/scandalizing-biosimilar-drugs-with-safety-concerns/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why does the Government divert focus on to fringe issues to address critical healthcare concerns of the nation?</title>
		<link>http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation</link>
		<comments>http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/#comments</comments>
		<pubDate>Mon, 04 Oct 2010 01:00:42 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[address]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[critical]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[divert]]></category>
		<category><![CDATA[focus]]></category>
		<category><![CDATA[fringe]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[Issues]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[nation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[spend]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=366</guid>
		<description><![CDATA[The Department of Industrial Policy and Promotion (DIPP) of the Ministry of Commerce and Industry of the Government of India has recently initiated a public debate through a ‘Discussion Paper on Compulsory Licensing (CL) of Patented Pharmaceutical Products’. The key &#8230; <a href="http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-does-the-government-divert-focus-on-to-fringe-issues-to-address-critical-healthcare-concerns-of-the-nation/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A brief history of the Indian Patent System from Indian Pharmaceutical Industry perspective, the concerns and opportunities.</title>
		<link>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities</link>
		<comments>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/#comments</comments>
		<pubDate>Thu, 29 Oct 2009 00:30:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2005]]></category>
		<category><![CDATA[3d]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[brief]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[history]]></category>
		<category><![CDATA[incremental]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[perspective]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[section]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=742</guid>
		<description><![CDATA[Although a comprehensive Act on Patents and Designs allowing product patents of drugs came into force in India in 1911, the first Patents Act of India was enacted in 1856.This Act gave a head start to the global pharmaceutical companies &#8230; <a href="http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-brief-history-of-the-indian-patent-system-from-indian-pharmaceutical-industry-perspective-the-concerns-and-opportunities/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
